0
Verrica Pharmaceuticals Inc. Banner Image

Verrica Pharmaceuticals Inc. has reached its limit for free report views

Work for Verrica Pharmaceuticals Inc.? Upgrade Your Profile and unlock all your annual reports.

Verrica Pharmaceuticals Inc.

  • Ticker VRCA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Verrica Pharmaceuticals Inc. Logo Image
  • 11-50 Employees
  • Based in West Chester, Pennsylvania
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received fromMore the FDA regarding the NDA for VP-102 on July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.
Verrica Pharmaceuticals Inc.

Most Recent Annual Report

Verrica Pharmaceuticals Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Verrica Pharmaceuticals Inc. has reached its limit for free report views.

Older/Archived Annual Reports